People · Operator
Named in public records as an officer, director or promoter · active 2016–2020 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ardelyx, Inc. | — | Pharmaceuticals | Series D+ | $210.4M | $3.9B | 2016 |
| Chinook Therapeutics U.S., Inc. | — | Biotechnology | Series D+ | $180.0M | $4.5B | 2019 |
| Mistral Therapeutics, Inc. | — | Biotechnology | Series B | $36.4M | $1.0B | 2018 |
| Jengu Therapeutics, Inc. | — | Biotechnology | Series A | $5.0M | $164.9M | 2020 |
Jeremy Caldwell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeremy Caldwell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 2 | 13 |
| Clare Ozawa | 2 | 8 |
| Srinivas Akkaraju | 1 | 10 |
| BRADLEY BOLZON | 1 | 10 |
| David Mott | 1 | 9 |
| David Collier | 1 | 8 |
| Annalisa Jenkins | 1 | 8 |
| Petpiboon Prasit | 1 | 7 |
| Gordon Ringold | 1 | 7 |
| Thomas Woiwode | 1 | 7 |
| Bradley J. Bolzon | 1 | 5 |
| THOMAS A COLL | 1 | 4 |
| Richard Rodgers | 1 | 4 |
| Sam Hall | 1 | 3 |
| Andrew King | 1 | 3 |
| David Rosenbaum | 1 | 3 |
| Peter G. Schultz | 1 | 3 |
| Jeff Jacobs | 1 | 2 |
| Robert Bazemore | 1 | 2 |
| Paul Korner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.